PDCD1 and colorectal carcinoma: Pembrolizumab, another anti-PD1 moAb, received approval on 29 June 2020, as a first-line treatment for patients with unresectable or metastatic MSI-H/dMMR CRC based on the KEYNOTE-177 study [124].